Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) – B. Riley cut their Q1 2023 earnings estimates for shares of Mirati Therapeutics in a report released on Sunday, January 22nd. B. Riley analyst K. Patel now expects that the biotechnology company will earn ($3.33) per share for the quarter, down from their prior estimate of ($3.32). B. Riley currently has a “Neutral” rating and a $56.00 target price on the stock. The consensus estimate for Mirati Therapeutics’ current full-year earnings is ($13.50) per share. B. Riley also issued estimates for Mirati Therapeutics’ Q2 2023 earnings at ($3.30) EPS, Q3 2023 earnings at ($3.27) EPS, Q4 2023 earnings at ($3.23) EPS, FY2023 earnings at ($13.12) EPS and FY2024 earnings at ($10.10) EPS.
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($3.09) EPS for the quarter, topping the consensus estimate of ($3.46) by $0.37. Mirati Therapeutics had a negative return on equity of 60.40% and a negative net margin of 6,253.81%. The firm had revenue of $5.43 million for the quarter, compared to the consensus estimate of $4.72 million.
Mirati Therapeutics Stock Performance
MRTX opened at $49.36 on Wednesday. The stock’s 50 day simple moving average is $56.60 and its 200 day simple moving average is $66.49. Mirati Therapeutics has a 1 year low of $32.96 and a 1 year high of $124.81.
Hedge Funds Weigh In On Mirati Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of Mirati Therapeutics by 41.7% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,481 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 730 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Mirati Therapeutics by 77.3% during the second quarter. Virtus ETF Advisers LLC now owns 1,975 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 861 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Mirati Therapeutics during the third quarter valued at approximately $42,000. Credit Suisse AG increased its position in shares of Mirati Therapeutics by 0.3% during the second quarter. Credit Suisse AG now owns 442,710 shares of the biotechnology company’s stock valued at $29,719,000 after acquiring an additional 1,123 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Mirati Therapeutics by 77.5% during the second quarter. US Bancorp DE now owns 3,369 shares of the biotechnology company’s stock valued at $227,000 after acquiring an additional 1,471 shares in the last quarter.
Insider Buying and Selling
In related news, Director Julie M. Cherrington sold 2,546 shares of the stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $44.66, for a total value of $113,704.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Mirati Therapeutics news, Director Julie M. Cherrington sold 2,546 shares of the firm’s stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $44.66, for a total transaction of $113,704.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David D. Meek sold 3,179 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $42.38, for a total transaction of $134,726.02. Following the transaction, the chief executive officer now directly owns 61,792 shares of the company’s stock, valued at approximately $2,618,744.96. The disclosure for this sale can be found here. Insiders sold a total of 103,593 shares of company stock valued at $8,465,677 over the last three months. Corporate insiders own 3.47% of the company’s stock.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.
- Get a free copy of the StockNews.com research report on Mirati Therapeutics (MRTX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.